Therapeutic peptides are oligomers or short polymers of amino acids used for various
medical purposes. Peptide-based treatments have evolved considerably due to new …

The platelet glycoprotein (GP) IIb/IIIa integrin plays a key role in mediating platelet
aggregation. Blockade of the platelet GP IIb/IIIa receptor prevents arterial thrombosis in …

Background The primary cause of acute coronary syndromes is the development of a
thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the …

Eptifibatide, a cyclic peptide, is a highly specific, intravenously administered glycoprotein
(GP) IIb/IIIa receptor antagonist. By preventing fibrinogen binding to the GP IIb/IIIa receptor …

Eptifibatide Page 1 lying mechanism leading to these life-threatening clinical events (2). Platelet
aggregation that occurs at the site of atherosclerotic plaque rupture initiates a cascade of …

Platelet-dependent thrombosis plays a central role in the pathophysiology of myonecrosis in
both percutaneous coronary interventions (PCIs) and acute coronary syndromes (ACS) …

Eptifibatide, a synthetic peptide inhibitor of the platelet glycoprotein IIb/IIIa receptor, has
been studied as an antithrombotic agent in a variety of acute ischemic coronary syndromes …

Eptifibatide, a molecule isolated from the venom of the southeastern pygmy rattlesnake,
selectively inhibits the platelet receptor IIb/IIIa. The safety and clinical efficacy of eptifibatide …

Background Pharmacodynamics of eptifibatide, a cyclic heptapeptide antagonist of platelet
glycoprotein IIb/IIIa, are substantially altered by anticoagulants that chelate calcium …

ABSTRACT Glycoprotein (GP) IIb/IIIa receptor antagonists inhibit the binding of ligands to
activated platelet GP IIb/IIIa receptors and, therefore, prevent the formation of platelet …